[{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"NewG Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ NewG Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ NewG Lab"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"NewG Lab Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ NewG Lab Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ NewG Lab Therapeutics"},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Guardant Health \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Guardant Health \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nippon Kayaku","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Nippon Kayaku","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nippon Kayaku"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nuvation Bio"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nuvation Bio"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvation Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvation Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"ROS-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"ROS-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Taletrectinib","moa":"ROS-1","graph1":"Oncology","graph2":"Phase III","graph3":"Nuvation Bio","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Nuvation Bio \/ Sagard Healthcare Partners"}]
Find Clinical Drug Pipeline Developments & Deals for Taletrectinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
